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Aggressive venous neointimal hyperplasia in a pig model of data, it has been estimated that vascular access dysfunc-
arteriovenous graft stenosis. tion is responsible for approximately 20% of all hospital-
Background. Vascular access dysfunction is the most impor- izations in the ESRD population [2] at a total cost oftant cause of morbidity and hospitalization in the hemodialysis
approximately 1.7 billion dollars per year [3]. The mostpopulation in the United States at a cost of well over one billion
common form of vascular access procedure performeddollars per annum. Venous neointimal hyperplasia character-
ized by stenosis and subsequent thrombosis, is the major cause in chronic hemodialysis patients in the United States is
of polytetrafluoroethylene (PTFE) dialysis graft failure. Despite the arteriovenous polytetrafluoroethylene (PTFE) graft,
the magnitude of the problem, there are currently no effective
which accounts for approximately 70% of all hemodialy-therapies for the prevention or treatment of venous neointimal
sis access [4]. Unfortunately, the current one- and two-hyperplasia in PTFE dialysis grafts. We believe that this is partly
due to the lack of a validated large animal model of arteriove- year primary patency rates for arteriovenous PTFE dial-
nous stenosis that could be used to test out novel interventions. ysis grafts are a dismal 50% and 25%, respectively [4].
Methods. Seven-centimeter PTFE loop grafts were placed Graft thrombosis is the cause of 80% of all vascular accessbetween the femoral artery and vein of domestic pigs. The grafts
dysfunction and in over 90% of thrombosed grafts thewere removed at 2, 4, 7, 14 and 28 days after surgery and sub-
underlying pathology is a stenosis due to venous neointi-jected to a detailed histological and immunohistochemical ex-
amination. mal hyperplasia (VNH), either at the venous anastomotic
Results. Significant neointimal hyperplasia and venous ste- site or in the proximal vein [5].
nosis developed by 28 days at the graft-vein anastomosis. There
We and others have previously shown that venouswas minimal neointimal hyperplasia at the graft-artery anasto-
neointimal hyperplasia (VNH) in the setting of arterio-mosis. Venous neointimal hyperplasia (VNH) was characterized
by (a) the presence of smooth muscle cells/myofibroblasts; (b) venous hemodialysis grafts is characterized by smooth
angiogenesis within both the neointima and adventitia; and (c) muscle cells, neointimal and adventitial microvessels and
the presence of an active macrophage cell layer lining the PTFE extracellular matrix components [6–10] However, de-graft material. These results are very similar to the human
spite a reasonable knowledge of the pathology of VNH,lesion previously described by us in dialysis patients.
there are still no effective interventions for either theConclusions. We have developed and validated a pig model
of venous neointimal hyperplasia that is very similar to the prevention or treatment of hemodialysis vascular access
human lesion. We believe that this is an ideal model in which dysfunction. This is particularly unfortunate, as VNH in
to test out novel interventions for the prevention and treatment
the setting of hemodialysis grafts appears to be a far moreof clinical hemodialysis vascular access dysfunction.
aggressive lesion as compared to the more common arte-
rial neointimal hyperplasia that occurs in peripheral by-
pass grafts. Compare the 50% one year primary patencyHemodialysis vascular access dysfunction is the single
in PTFE dialysis access grafts with an 88% five year pat-most important cause of morbidity in the 230,000 hemo-
ency for aortoiliac grafts [11] and a 70 to 80% one yeardialysis patients in the United States [1]. Using Medicare
patency for femoro-popliteal grafts [12]. Venous stenoses
in the setting of dialysis access grafts also have a poorer
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response to angioplasty (40% three month survival ifmodel, microvessel formation, vascular access dysfunction, hemodialysis,
PTFE failure, graft thrombosis. thrombosed [13] and a 50% six month survival if not
thrombosed [14–16]) as compared to arterial stenoses.Received for publication December 21, 2001
We believe that the lack of effective therapies forand in revised form June 10, 2002
Accepted for publication July 22, 2002 VNH and venous stenosis in PTFE dialysis grafts is due
to (a) a lack of appreciation of the fact that venous 2002 by the International Society of Nephrology
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stenosis may be very different from the more common embedded sections were then used for histological, mor-
phometric and immunohistochemical analyses. Two addi-arterial stenosis at the graft-artery anastomosis [17] and
(b) the absence (until recently) of a validated large ani- tional pigs were injected with bromodeoxyuridine (BrDU;
50 mg/kg) IP 24 hours prior to sacrifice at 28 days as partmal model of VNH to test out novel interventions. We
report the development and validation of a pig model of of a concurrent study. Data from these pigs are described
in order to assess the degree of cellular proliferation inVNH and venous stenosis in the setting of arteriovenous
PTFE dialysis grafts, that is very similar to the human this model.
lesion previously described by us [8, 9].
Terminology
The artery and vein in this study will be described in
METHODS
terms of whether or not they are upstream or down-
Animals stream of the graft-vein or graft-artery anastomosis. Fig-
ure 2 identifies the four regions described in this study.Three-month-old, 30 kilogram, Yorkshire Cross domes-
tic swine were purchased from Yeazel and Co. (Wolver- Region A is defined as the downstream vessel. In the
case of the vein this will be proximal to the graft-veinton, OH, USA) and kept in standard animal care facilities
at the University of Cincinnati Medical Center. anastomosis (GVA), while in the case of the artery it is
the distal to the graft-artery anastomosis (GAA). Regions
Surgery B and C encompass the graft-vessel anastomosis. Region
B is defined as the intra-graft portion of the graft-vesselPigs were anesthetized and intubated with a combina-
tion of xylazine, telazol and atropine. Isoflurane was used anastomosis, while Region C is defined as the vessel-
wall portion of the graft-vessel anastomosis. Finally, Re-for maintenance anesthesia. Seven cm, 4 mm ID, loop
PTFE grafts (30 micron internodal distance) were placed gion D is defined as upstream vessel. In the case of the
vein this will be distal to the GVA, while in the case ofbetween the femoral artery and femoral vein using stan-
dard surgical techniques (Fig. 1 a, b). End-to-side anasto- the artery it is proximal to the graft-artery anastomosis.
moses were made with a continuous 6/0 polypropylene
Luminal stenosissuture. Special care was taken to ensure that there were
no kinks in the graft and that it was well placed in a A visual estimate of the amount of luminal stenosis
within the intra-graft region of the graft-vessel anasto-created pocket. The fascia and skin were closed in layers
using 3/0 Dexon and silk. Buprenex was used for post- mosis was made by a pathologist (SCH).
operative analgesia as needed. All pigs were adminis-
Immunohistochemical analysestered Aspirin EC 325 mg from day 1 to the time of
sacrifice, together with a single dose of intra-operative Tissue samples from the graft-vein and graft-artery
anastomoses were assessed for expression of alpha-smoothheparin (150 U/kg). Graft patency was confirmed im-
mediately after surgery and then every three days by muscle actin (a smooth muscle cell and myofibroblast
marker, 1A4, 1:200; Dako, Carpinteria, CA, USA) andauscultation. We decided to use aspirin in our model as
we believed that the benefits of the anti-platelet and von Willebrand factor (an endothelial cell marker, poly-
clonal, 1:500; Dako), using a standard automated strep-anti-thrombotic effects of aspirin in the first week out-
weighed any later effect on smooth muscle cell prolifera- tavidin biotin technique (Ventana 320ES automated im-
munostainer; Tucson, AZ, USA). Two additional pigstion [18, 19]
were injected with BrDU (a marker of cellular prolifera-
Study design tion), and grafts from these animals also were assessed
using an antibody to BrDU (clone3D9, 1:500; obtainedNine pigs were utilized in this validation study and a
total of 18 grafts were placed. Pigs were sacrificed at 2, from Azra Raza, Rush Presbyterian St. Luke). Briefly,
following deparaffinization and hydration, slides were4, 7, 14 and 28 days post-surgery (one pig at the 2-day
time point and 2 pigs at each of the other time points). washed and underwent protease digestion (if required
for a particular primary antibody). Slides were then incu-One graft at each of the 7- and 14-day time points was
lost due to thrombosis as a result of a technical failure. bated with the primary antibody for 32 minutes, with
the biotinylated secondary antibody blend (anti-rabbitThese grafts were excluded from the study. At the time
of sacrifice the animals were anesthetized as above and Ig, anti-mouse IgG and anti-mouse IgM) for eight min-
utes and with the streptavidin/horseradish peroxidase forthe graft was carefully dissected out. Following a lethal
injection of sodium pentothal, the entire graft together eight minutes. All incubations were performed at 37C
with constant movement, and with appropriate washeswith attached artery and vein was removed (Fig. 1c). The
graft was cut 1 cm above the arterial and venous anastomo- between each step. The slides were then developed with
a diaminobenzidine/hydrogen peroxide mixture for fourses as shown in Figure 1c, following which it was fixed in
formalin and sectioned as described in Figure 2. Paraffin minutes, counterstained with hematoxylin, dehydrated
Fig. 1. Surgical techniques. (a ) Suturing of the polytetrafluoroethylene (PTFE) graft to the venous anastomosis. (b ) Completed PTFE graft lying
in its pocket. (c ) Dissected PTFE graft prior to sectioning. The red dotted lines indicate the usual site where the graft is cut to obtain a Y-shaped
specimen for further analysis.
Fig. 3. Neointimal hyperplasia in the pig model. (a–c) The temporal course of venous neointimal hyperplasia in our pig model (H&E stain; 50).
All of the sections are from the site of the graft-vein anastomosis (corresponding to Region B in Fig. 6). Note that at Day 2 post-surgery (a) there
is no encroachment of neointima into the graft. At 14 days (b), approximately a third of the graft-vein anastomosis (GVA) is covered by venous
neointima (extent of arrow), while at 28 days (c) the GVA is almost totally occluded (extent of arrow; H&E stain;50. (d) Graft-artery anastomosis
(GAA) neointima at day 28 after graft placement shows minimal neointimal hyperplasia at the arterial anastomosis (H&E 50). Compare with
panel c. (e) GVA neointima at day 28 documents prominent angiogenesis (arrow) within the neointima together with mononuclear cells lining
and infiltrating into the graft (H&E, 1000). ( f ) GVA neointima showing a large number of -smooth muscle cells in our pig model (H&E,
1000). (g and h) Significant neointimal and advential proliferation can be seen at day 28. (g) Colocalization (vertical arrow) of brown endothelial
cells (vWF) and blue proliferating cells (BrDU) within the adventia, denoting active angiogenesis in this region (995). Also note the large number
of blue proliferating cells that are not associated with brown endothelial cells, indicating active proliferation within advential fibroblasts and
myofibroblasts (horizontal arrow). (h) Double stain for proliferating cells in blue (BrdU) and endothelial cells in brown (vWF) demonstrates both
endothelial cell proliferation within microvessels (angiogenesis, vertical arrow) and proliferation of smooth muscle cells/myofibroblasts (horizontal
arrow; 1000). (i) Low power view of the graft-vein anastomosis from a human dialysis patient with venous stenosis (H&E; 50). Note the
remarkable similarity between our 28 day pig sample (c) and the human sample (i).
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on the amount of luminal stenosis within the graft at the
GVA only (a cut-off point of 25% downstream venous
intra-graft luminal stenosis was used for this analysis);
and (3) a paired t test was used to assess differences in
luminal stenosis, smooth muscle cells and microvessels,
between the vein and the artery in the same pig. A P
value of 0.05 was considered to be significant for all
the analyses.
RESULTS
Our main finding was that of very significant luminal
stenosis due to neointimal hyperplasia at the graft-vessel
anastomosis (intragraft portion), especially at the down-Fig. 2. Tissue processing. Diagrammatic representation of the graft-
stream (venous) anastomosis. In contrast, there was min-vein anastomosis in our pig model, demonstrating how the tissue sam-
ples are cut at the venous anastomosis. The terminology used in this imal luminal stenosis at 28 days (our longest time point)
study includes: A, downstream or proximal vein; B, intragraft portion in either the downstream or upstream vessel at both theof the graft-vein anastomosis; C, venous portion of the graft-vein anasto-
arterial and venous anastomoses. At a histological level,mosis; D, upstream or distal vein.
neointimal hyperplasia at the graft-vessel anastomosis
in our pig model was comprised of smooth muscle cells
and microvessels, together with extracellular matrix com-
with graduated alcohol and xylene, and mounted using ponents (Fig. 3 a-h). There was also a mononuclear cell
a xylene-based medium. A brown color indicated a posi- infiltrate that lined the PTFE graft material on both
tive stain. Negative controls were performed on each run sides and infiltrated into the interstices of the graft. The
by substituting the primary antibody with a relevant non- following paragraphs describe the pattern of neointimal
specific immunoglobulin (rabbit polyclonal or mouse hyperplasia at the venous and arterial anastomoses in
monoclonal). In addition, positive control tissue (gut, our pig model. The description will focus on the four re-
lymph node and spleen) was used to document the effi- gions defined in Figure 2 and the Methods section, with
cacy of each antibody. an emphasis on the graft-vein anastomosis, which is the
focus of this study and had the most significant amount
Parameters of neointimal hyperplasia and luminal stenosis.
First, at the intra-graft portion of the graft-vessel ana-
Graft-vessel anastomosis (intragraft region,stomosis (Region B in Fig. 2), two parameters were as-
Area B in Fig. 2)sessed: (a) a visual estimate of luminal stenosis; (b) a
visual estimate of the percentage of smooth muscle cells Luminal stenosis. (a) Venous anastomosis. There was
and endothelial cells (microvessels) to the total number a graded increase in the amount of intragraft luminal
of cells within the graft neointima. Second, the vessel stenosis from 0% at day 2 to 52.5% at day 28. Luminal
wall portion of the graft-vessel anastomosis (Region C in stenosis at 28 days was significantly greater than at the
Fig. 2) and downstream (Region A in Fig. 2) and up- 2, 4, 7 and 14 days (ANOVA, P  0.004; Table 1 and
stream (Region D in Fig. 2) vessel at both the GVA Figs. 3a-c and 4A).
and GAA were assessed for (a) the number of smooth (b) Arterial anastomosis. Luminal stenosis of greater
muscle cell layers in the neointima, and (b) for the pres- than 5% was present only at the 28-day time point (Table
ence of microvessels in and around the adventitia. The 1, Figs. 3d and 4a). In contrast to the venous anastomosis
number of microvessels was graded on a semiquantita- there was no statistically significant difference between
tive 0 to 5 scale, with 0 being no microvessels and 5 the magnitude of luminal stenosis at the GAA at the
being significant adventitial and peri-adventitial vascu- different time points (Fig. 4A).
larization. Smooth muscle cell/myofibroblast component. (a) Ve-
nous anastomosis. Alpha actin-positive smooth muscle
Comparisons made and statistics used cells or myofibroblasts were the predominant cell type
Three methods were used to assess the statistics: (1) within the venous neointima, comprising as much as 90%
the analysis of variance (ANOVA) was used to identify and 72.5% of all neointimal cells at the 14- and 28-day
differences between the above parameters at each of the time points. Both the 14- and 28-day time points had a
five time points in this study; (2) an unpaired t test was significantly greater proportion of alpha actin-positive
used to analyze differences in the above parameters cells as compared to the 2-, 4-, and 7-day time points
(ANOVA, P  0.0009; Table 1 and Figs. 3e-f and 4B).when the samples were divided into two groups based
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Table 1. Luminal stenosis, smooth muscle cell expression and microvessel formation in the intragraft portion of the
graft-vessel anastomosis (Area B in Fig. 2)
Time LS% V LS% A %SMA V %SMA A %ENDO V %ENDO A
D 2 0.0 0.0 5.00.0 0.0 7.52.5 0.0
D 4 2.80.8 0.70.7 3.33.3 0.0 0.0 0.0
D 7 0.0 0.0 13.313.3 0.0 8.38.3 0.0
D 14 10.05.0 1.01.0 90.05.8 26.726.7 4.72.7 0.0
D 28 52.510.1 8.55.6 72.511.1 67.56.3 40.012.1 14.07.9
Abbreviations are: %LS V, percent luminal stenosis at the graft-vein anstomosis (GVA); %LS A, percent luminal stenosis at the graft-artery anastomosis (GAA);
%SMA V, percentage of neointima made up of smooth muscle cells at the GVA; %SMA A, percentage of neointima made up of smooth muscle cells at the GAA;
%ENDO V, percentage of neointima made up of endothelial cells (microvessels) at the GVA; %ENDO A, percentage of neointima made up of endothelial cells
(microvessels) at the GAA. All numbers are mean percentage  SE.
Fig. 4. Validation of the pig model. Symbols are: () vein; () artery. (A) Percent luminal stenosis at the graft-vein anastomosis (GVA) and
graft-artery anastomosis (GAA) in the pig model. Note the significant increase in VNH at the 28-day time point compared to all other time points
(*P  0.0004). There also is significantly more luminal stenosis at the GVA than the GAA at 28 days (#P  0.026). (B) Smooth muscle cells as
a percentage of total neointimal volume. Note that the increasing contribution of smooth muscle cells to the total neointimal volume (*P  0.0009,
compare days 14 and 28 to earlier time points at the GVA). A similar trend was observed for the GAA, but was significant only for a 28 day vs.
days 2 and 4 time point (P  0.04). (C ) Microvessels as a percentage of total neointimal volume. Note the statistically significant increase in
the microvessel component of the neointima at 28 days, at the GVA vs. all other venous time points (*P  0.04). This is not the case for the
GAA. There also is a trend towards a statistically significant difference between the microvessel component at the GVA and GAA at 28 days
(40  12 vs. 14  8, #P  0.051).
(b) Arterial anastomosis. As for the venous anastomo- the luminal and adventitial surfaces of the PTFE graft
(Fig. 3e).sis, alpha actin-positive cells were the predominant cell
type within the venous neointima, comprising 26% and Proliferating cells. Although we did not inject the pigs
described in this study with BrDU to assess cellular pro-67% of all neointimal cells at the 14- and 28-day time
points. However, the only statistically significant compar- liferation, we have done so in a concurrent study. Figure
3 panels f, g and h show examples of double stainingisons were for the 28-day time point compared with the
2- and 4-day time points (ANOVA; P  0.04; Table 1 experiments with BrDU and vWF in a pig that was sacri-
ficed 28 days after graft implantation. Note the promi-and Fig. 4B).
Endothelial cell/microvessel component. (a) Venous nent co-localization of BrDU and vWF in both neointi-
mal (Fig. 3h) and adventitial (Fig. 3g) microvesselsanastomosis. Endothelial cells and microvessels com-
prised less than 10% of neointimal cells at all time points indicating active endothelial cell proliferation at both
these sites. Also, note that a number of BrDU positiveup to and including 14 days. At the 28-day time point,
however, the percentage of endothelial cells to total cells cells are vWF negative indicating the presence of cellular
proliferation in smooth muscle cells, myofibroblasts andaveraged 40%, which was significantly higher than the
values for the 2- to 14-day time points (ANOVA, P  macrophages, which are the other cell types that charac-
terize this lesion.0.04; Table 1, and Figs. 3 e, h, and 4C).
(b) Arterial anastomosis. vWF staining for endothelial Differences in smooth muscle cell and endothelial cell
expression in grafts with varying degrees of luminal steno-cells was present only at the 28-day time point where it
comprised 14% of all neointimal cells (Table 1). sis. In an attempt to assess possible mechanisms respon-
sible for neointimal hyperplasia in the pig model theMononuclear cells and macrophages. A prominent
layer of macrophage-like mononuclear cells lined both grafts were divided into two groups based on the amount
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Table 2. Neointimal smooth muscle cell layers and adventitial/
peri-adventitial microvessels
ADV ADV
SMA (N ) SMA (N ) vessels vessels
Time V A (V) (A)
Vessel portion of the graft-vessel anastomosis (Area C in Fig. 2)
D 2 6.0 4.01.0 1.50.5 0.0
D 4 6.251.6 2.00.7 1.00.6 0.50.5
D 7 9.33.0 2.30.3 2.30.3 0.50.5
D 14 8.73.2 2.01.2 1.70.3 0.70.3
D 28 5.81.50 70.0 2.50.6 1.00.0
Downstream vessel (Area A in Fig. 2)
D 2 5.50.5 4.52.5 1.01.0 0.0
D 4 6.01.0 1.30.3 2.00.6 0.0
D 7 7.72.2 1.00.0 1.30.3 0.0
D 14 6.02.0 2.70.7 1.30.3 0.0
D 28 13.35.84 4.70.9 3.00.4 1.01.0
Upstream vessel (Area D in Fig. 2)
D 2 9.0 2.01.0 1.0 0.0
D 4 4.50.5 1.80.3 2.50.5 0.0
D 7 1.70.3 0.0
D 14 7.02.0 5.52.5 1.00.0 0.50.5
D 28 7.33.8 5.01.3 2.30.3 0.50.3
Abbreviations are: SMA (N ) V, number of venous neointimal smooth muscle
cell layers; SMA (N ) A, number of arterial neointimal smooth muscle cell layers;
Fig. 5. Smooth muscle cell and endothelial cell (microvessel) expres- ADV vessels (V), score for venous adventitial and peri-adventitial microvessels;
ADV vessels (A), score for arterial adventitial and peri-adventitial microvesselssion as a function of luminal stenosis at the graft-vein anastomosis. (A)
(score for adventitial microvessels is on a 0–5 scale).Grafts with greater than 25% luminal stenosis had a predominance
of endothelial cells (microvessels) within the neointima (P  0.0012)
compared to grafts with less than 25% luminal stenosis. (B) This was
not the case for smooth muscle cells within the neointima.
to arterial neointima (40  12.1 vs. 14  7.9%), this did
not achieve statistical significance (Fig. 4C, P  0.051).
of luminal stenosis at the graft-vein anastomosis, using Upstream and downstream vessel, including vessel at
a cut off value of 25%. Grafts in the two groups were the anastomosis (Areas A, C and D in Fig. 2)
then compared with each other with regard to differences
This section summarizes the results (at different timein the contribution of endothelial and smooth muscle
points) for the semicircle of vessel at the graft-vesselcells to neointimal hyperplasia at the graft-vein anasto-
anastomosis (Area C in Fig. 2, Table 2) and for down-mosis only. This analysis was not performed for the graft-
stream (Area A in Fig. 2, Table 2) and upstream (Areaartery anastomosis due to the relatively small amounts
D in Fig. 2, Table 2) vessel. The results for (a) numberof luminal stenosis at this site (Table 1 and Fig. 3d).
of smooth muscle layers within the neointima and (b)Figure 5 summarizes these differences. Note that grafts
the number of microvessels within the adventitia andwith more than 25% luminal stenosis at the graft-vein
peri-adventitial region are described in Table 2. Signifi-anastomosis had a significantly greater percentage of
cant differences between the assessed time points wereendothelial cells (microvessels) within the venous neoin-
very few and included:tima as compared to grafts that had less than 25% luminal
stenosis (Fig. 5A). There were no differences in the per-
(a) The number of smooth muscle cell layers in upstreamcentage contribution of smooth muscle cells to the ve-
artery was significantly more at the 28-day time pointnous neointima, based on the degree of luminal stenosis
as compared to days 4 and 7, and at the 14-day time(Fig. 5B).
point as compared to day 4.Differences in luminal stenosis, smooth muscle and en-
(b) The number of smooth muscle cell layers in down-dothelial cell (microvessel) expression between the graft-
stream artery was significantly more at the 2 and 28vein and graft-artery anastomoses at 28 days. A paired
day time-points as compared to days 4 and 7.t test was used for this analysis. As shown in Figure 4A,
(c) The number of adventitial and peri-adventitial ves-there was significantly more luminal stenosis at the GVA
sels in downstream vein at day 28 was significantlyat day 28 as compared to the contralateral GAA (52.5
greater than at days 2, 7 and 14.10.1 vs. 8.5 5.6%, P  0.027). There was no difference
in the expression of smooth muscle cells between the
When the grafts were divided into two groups basedartery and vein (Fig. 4B). Finally, while there was a
on the cutoff of 25% luminal stenosis at the graft-veinstrong trend toward a greater number of endothelial cells
(microvessels) within the venous neointima as compared anastomosis (intragraft portion) and then assessed for
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differences in upstream and downstream vein and in cells, suggesting that cellular proliferation could play a
the vein at the GVA, the only statistically significant key role in the pathogenesis of this lesion. Of special
difference was an increase in the amount of adventitial interest was the presence of a large number of microves-
and peri-adventitial microvessels (3  0.4 vs. 1.45  0.2; sels within both the neointima and adventitia/peri-adven-
P  0.0066) and in the number of smooth muscle cell titia. Elegant studies by the Folkman group have demon-
layers (13.33  5.8 vs. 6.36  0.8; P  0.044) in down- strated that neoplastic tissue growth is dependent on the
stream vein, in grafts with greater than 25% luminal presence of microvessels (angiogenesis) [20, 21]. Whether
stenosis at the GVA. This analysis was not performed this paradigm also holds true for non-neoplastic tissue
for the arterial anastomosis in view of the minimal neoin- growth is currently unknown, although experiments by
timal hyperplasia at this site. Moulton et al have demonstrated that atherosclerosis in
apolipoprotein (Apo) E knockout animals is dependent
on angiogenesis [22]. In the particular context of the pigDISCUSSION
model, the presence of a proportionately larger number
As a first step toward a better understanding of the of microvessels in grafts with more luminal stenosis sug-
pathogenesis of venous neointimal hyperplasia in arte- gests a link between angiogenesis and neointimal hyper-
riovenous grafts, we have developed and validated a pig plasia in this model.
model of venous neointimal hyperplasia. Our ultimate
goal is to use information obtained from this model to Adventitial remodeling
devise novel therapies for the prevention and treatment There has recently been a great deal of interest in
of clinical hemodialysis vascular access dysfunction. adventitial remodeling, whereby it is postulated that the
final degree of luminal stenosis is dependent both on theSimilarities between the pig and human lesions
magnitude of neointimal hyperplasia and the pattern ofOur results indicate that the histological lesions of
adventitial or vascular remodeling [23–25]. Thus, in thevenous neointimal hyperplasia in the pig model are very
presence of equivalent amounts of neointimal hyperpla-similar to those human dialysis grafts described by our
sia, vascular constriction will result in a smaller luminaland other groups [6–10]. Specifically, both lesions are
area, while vascular dilation will result in a larger luminalcomposed of smooth muscle cells and myofibroblasts,
area [26]. In the setting of experimental coronary angio-microvessels, macrophages and extracellular matrix com-
plasty, it is currently believed that vascular or adventitialponents (compare Fig. 3 panel a to i). While the develop-
remodeling is responsible for approximately 50% of finalment of significant VNH at four weeks is generally more
luminal stenosis [23]. In this regard, Kwon et al haveaggressive than the human lesion, it is important to point
demonstrated that the amount of adventitial angiogen-out that Zaman et al observed the aggressive develop-
esis is directly correlated to the final degree of luminalment of venous stenosis in dialysis patients within four
stenosis in a balloon angioplasty model [27]. The pres-weeks (abstract; Zaman et al, J Am Soc Nephrol 10:223A,
ence of a large number of adventitial microvessels in our1999). In contrast to the actual clinical setting of hemodi-
pig model, therefore, could be linked to a propensityalysis access dysfunction, our pigs were not uremic and
of the venous adventitia to undergo angiogenesis, withneedles were not inserted into the graft. However, the
subsequent scarring and adverse adventitial remodeling.marked similarities between the pig and human lesions,
This could be a factor that is responsible for the aggres-despite these differences, make us even more confident
sive course of venous stenosis in clinical PTFE dialysisabout the relevance of this model to the clinical scenario.
grafts and could be a potential target for therapeuticWe also note that our model focuses primarily on the
intervention in our pig model.graft-vein anastomosis, with minimal findings in down-
stream vein. Clinical hemodialysis access stenosis on the
Differences between luminal stenosis at the graft-veinother hand, occurs both at the GVA and downstream
and graft-artery anastomosisvein. This difference could be due to the relatively short
In keeping with the clinical presentation of stenosis at(28 day) validation period. Studies are underway in a
the GVA in hemodialysis patients, there was significantlygroup of pigs over a longer period of time to see whether
greater luminal stenosis at the outflow GVA as comparedthey develop stenosis in the downstream vein. We be-
to the inlet GAA (Fig. 4A). Once again, this suggests thatlieve that the many similarities between the human lesion
our model is representative of the clinical lesion. Interest-and our pig model strongly support the use of this model
ingly, there was a trend (albeit not statistically significant;for the evaluation of novel therapeutic interventions to
P  0.051) toward a larger percentage of microvesselsprevent hemodialysis vascular access dysfunction.
within the venous neointima as compared to the arterial
Cellular proliferation and angiogenesis neointima in the pig model at 28 days. This suggests
that angiogenesis could be the defining factor in theA key feature of the model was the presence of a large
number of proliferating endothelial and smooth muscle pathogenesis of the lesion and that the increased angio-
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genesis in the vein could be responsible for the increase that the in stent restenosis model could respond
in luminal stenosis at the GVA as compared to the GAA. very differently to interventions that target venous
Clearly, there are a number of upstream events that also neointimal hyperplasia, as compared to a non-stent
could be responsible for the aggressive venous lesion, model. Surprisingly, even with the use of stents,
including very different hemodynamic flow patterns at only one of five dogs developed thrombosis with
the inlet GAA as compared to the outlet GVA . Whether follow-up periods for as long as one year [29].
this difference in hemodynamic stress results in a differ- This would make it very difficult to do pragmatic
ent pattern of venous endothelial and smooth muscle intention to treat analyses with graft thrombosis
cell activation at the GVA is unknown. as the clinical end point in this model. In marked
contrast, the pig model lesion is an aggressiveComparisons between the pig model and previously
lesion with significant luminal stenosis within 28described dog and sheep models of arteriovenous
days.graft stenosis
(4) A salient feature of the sheep model is the pres-
To date, animal models of arteriovenous graft stenosis ence of attached and organized thrombus that
have been described in the dog [6, 28, 29] and in the contributed significantly to luminal stenosis [30].
sheep [30]. We believe that the pig model described in
This is never seen in dialysis patients with patent
our current study has a number of advantages over these
but dysfunctional grafts who are undergoing an-two previously described models. These include:
gioplasty. The presence of thrombus that is a rich
source of inflammatory mediators could poten-(1) The pig is currently the animal model of choice
tially alter the pathogenesis of luminal stenosis infor interventions targeting the lesion of coronary
the sheep model as compared to the human set-angioplasty restenosis [30–34]. We believe that this
ting. In addition, bone formation described in thewill result in the development of a variety of cellular
sheep model is not seen in dialysis patients.and molecular reagents targeted at the study of
biological mediators in the pig (U.S. Pig Gene Map-
Thus, the pig model of arteriovenous graft stenosisping Program web site, http://www.genome.iastate.
appears to have definite advantages over some of theedu/resources/index.html). These technologies then
other models currently available for the study of venouscould be applied to further elucidate the mecha-
stenosis, particularly with regard to histological andnisms of venous stenosis and venous neointimal
hyperplasia in the pig model. The above is not true pathophysiological similarities with human neointimal
for either the sheep or dog models. hyperplasia.
(2) The response of pig vessels to injury is believed
Conclusionsto be more akin to that of humans, at least as com-
pared to the dog. Schwartz et al have demonstrated We believe that the development and validation of a
that there is a direct and significant correlation large animal model of venous neointimal hyperplasia
between increasing coronary balloon angioplasty and venous stenosis in the setting of arteriovenous grafts
pressures and the magnitude of the restenotic le- is an important first step toward (1) achieving a better
sion in pigs, which is similar to the clinical situation understanding of the pathogenesis of venous stenosis and
in humans. This correlation does not occur in dogs venous neointimal hyperplasia in arteriovenous PTFE
[35, 36]. grafts, and (2) testing out novel interventions for the
(3) The lesion of venous stenosis and venous neointi- treatment of this condition (we have already obtained
mal hyperplasia in the dog model is a slowly devel-
some very positive results with external beam radiation
oping lesion. Indeed, in order to try and increase
in this model [37]). Finally, clinical dialysis access graftsthe progression of this lesion Trerotola et al placed
could be an ideal model for novel local therapies (suchstents at the GVA, one month after graft surgery
as radiation), in view of their superficial location (awayin an attempt to accelerate the development of
from vital organs) and easy access to both the patientvenous neointimal hyperplasia [28, 29]. The disad-
(in dialysis three times a week) and the graft (dialysisvantage of such a procedure, however, is that it
needles are placed within 3 to 4 cm of the site of lesion).makes the dog model, a model of in stent resteno-
We hope that our validated pig model of VNH andsis; this observation is discussed by Trerotola et
venous stenosis will provide a major impetus to the ne-al in their excellent article on this subject [29].
phrology and vascular surgery communities, for the de-Although the authors point out that at a histologi-
velopment and testing of novel local therapies for thecal level the lesion of in stent restenosis is similar
management of hemodialysis vascular access dysfunc-to the one that develops in the absence of stent
placement, this does not rule out the possibility tion.
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